Risk of neutropenia in psoriasis patients prescribed anti-IL-23 antibody in comparison with anti-IL-17 antibody or adalimumab based on real-world data from the MID-NET® in Japan

• Main Authors: Yusuke Okada (Author), Kazuhiro Kajiyama (Author), Chieko Ishiguro (Author), Takahiro Nonaka (Author), Tomomi Komaki (Author), Wataru Kuga (Author), Noriyuki Komiyama (Author), Toyotaka Iguchi (Author), Naoya Horiuchi (Author), Yoshiaki Uyama (Author)
• Format: Book
• Published: Taylor & Francis Group, 2024-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background To evaluate the risk of neutropenia during treatment with anti-IL-23 antibodies in patients with psoriasis.Method We conducted an observational study with cohort design using MID-NET® in Japan. We identified patients with psoriasis who were newly prescribed anti-IL-23 antibodies, anti-IL-...